Why Delays in IRB Review of Updated Informed Consent Forms Lead to Audit Findings

Introduction: The Role of Informed Consent Updates

Informed Consent Forms (ICFs) are critical documents that ensure participants are fully informed about trial risks, benefits, and procedures. When protocols are amended or new safety information arises, updated ICFs must be promptly reviewed and approved by Institutional Review Boards (IRBs) or Ethics Committees (ECs) before use. Regulatory authorities such as the FDA, EMA, and MHRA expect strict timelines for ICF review and approval.

Delays in IRB review of updated ICFs are a recurring audit finding. These delays often result in participants being enrolled or continued on studies using outdated forms, undermining ethical compliance and participant protection.

Regulatory Expectations for ICF Updates

Authorities outline strict requirements for the review of informed consent updates:

• All ICF amendments must be reviewed and approved by IRBs before implementation.
• Updated ICFs must reflect protocol amendments, new safety data, or regulatory guidance.
• Documentation of IRB approvals must be archived in the Trial Master File (TMF).
• Participants must be re-consented using the most recently approved ICF.
• Sponsors must verify site compliance with ICF approval timelines during monitoring.

The EU Clinical Trials Register reinforces the importance of ensuring that ICFs are accurate, updated, and ethically reviewed to maintain compliance.

Common Audit Findings on Delayed ICF Reviews

1. Outdated ICFs Used for Enrollment

Auditors frequently cite sites for enrolling participants with ICFs that had not yet been reviewed or approved by IRBs.

2. Delayed Documentation in TMF

Inspection reports often highlight missing or late filing of ICF approval letters in the TMF.

3. Lack of Participant Re-Consent

Sites are cited for failing to re-consent participants after approval of updated ICFs.

4. Sponsor Oversight Gaps

Sponsors are often cited for not verifying whether sites were using the most current IRB-approved ICFs.

Case Study: MHRA Audit on Delayed ICF Reviews

In a Phase II oncology trial, MHRA inspectors found that updated ICFs reflecting new SAE data were submitted to the IRB but not approved for over six weeks. During this time, 25 participants continued using outdated forms. The audit report classified this as a major finding, requiring re-consent of all affected subjects and implementation of preventive actions.

Root Causes of Delayed ICF Reviews

Root cause investigations typically reveal:

• Administrative backlogs within IRBs delaying review timelines.
• Poor site compliance with timely submission of updated ICFs.
• Absence of SOPs specifying timelines for submission and approval.
• Limited sponsor oversight of multi-site ICF approval timelines.
• Weak communication between sponsors, CROs, and IRBs regarding safety-related updates.